Search Journal-type in search term and press enter
SWJPCCS Manuscript Lists
Southwest Pulmonary and Critical Care Fellowships
In Memoriam
Social Media
RSS Feeds
Journal Club Archives
« December 2024 Pulmonary Case of the Month: Two Birds in the Bush Is Better than One in the Hand | Main | November 2024 Medical Image of the Month: A Case of Short Telomeres »
Tuesday
Nov052024

Glucagon‐like Peptide-1 Agonists and Smoking Cessation: A Brief Review

DateTuesday, November 5, 2024 at 8:58AM

By: Robbins RA

Abstract: The glucagon‐like peptide 1 (GLP-1) agonists such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®) have shown efficacy inducing weight loss in both diabetics and non-diabetics. According to the incentive sensitization theory of addiction, these drugs may prove useful in addictive disorders such as nicotine addiction. Animal data has been suggestive of a potential positive effect but early human studies have been mixed. This manuscript reviews the theory of addiction as well as the few animal and human studies available. Further human studies are needed to show GLP-1 agonist efficacy in smoking cessation.

URL: https://www.swjpcc.com/pulmonary/2024/11/5/glucagonlike-peptide-1-agonists-and-smoking-cessation-a-brie.html

|

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

Notify me of follow-up comments via email.